Abstract Details

Title Intracerebral Hemorrhage Associated with Cocaine Use

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P06 - (-)

Poster/Presentation
Number 273

Objective

Background BACKGROUND: Cocaine use is well known to cause ICH, most commonly secondary to acute hypertension. There is limited data on the clinical and radiological characteristics and outcome of patients with cocaine related ICH.

Design/Methods DESIGN/METHODS: Data was retrieved from our prospective database of patients with spontaneous ICH between January 2009 and June 2012. Urine drug screens were checked on admission on 92 percent (185/202) of patients with spontaneous intracerebral hemorrhage. Patients were divided into two groups based on Cocaine use. Admission hematoma volume was calculated using thin volumetric CT images via a special software. Clinical and laboratory parameters, medications, CT parameters, and in-hospital mortality were compared between the two groups using Fisher's test and t-test.

Results RESULTS: 185 patients with urine drug screen checks on admission were identified; 17 patients tested positive for cocaine. Patients with cocaine-related ICH were younger (52 ± 8 vs 64 ± 16, p=<0.001), more likely to be African American (88% vs 37% p=<0.001), use alcohol (65% vs. 19%, p<0.001) and tobacco (76% vs. 36%, p=0.03), had higher admission mean diastolic blood pressure in mm Hg (117 ± 24 vs 100 ± 25, p=0.009), and lower mean admission blood sugar in mg/dL (119 ± 33 vs 158 ± 71, p<0.001). Other clinical and laboratory parameters and radiological aspects (intraventricular extension, hydrocephalus, hematoma volume and location, and expansion) were similar between the two groups. Although patients with cocaine use were younger, mortality rates and percentage of patients with poor outcome at discharge were similar between the two groups.

Conclusions CONCLUSIONS: Primary preventive strategies are required to reduce the frequency of a potentially modifiable risk factor predisposing young patients to intracerebral hemorrhage with significant mortality and morbidity. Larger studies are needed to confirm our findings.

Authors/Disclosures
Jamil R. Dibu, MD (Cleveland Clinic Abu Dhabi) PRESENTER	No disclosure on file
Shadi Yaghi, MD (Hackensack Meridian Health)	Dr. Yaghi has nothing to disclose.
Eugene Y. Achi, MD (Cleveland Clinic Abu Dhabi)	No disclosure on file
Jeffrey A. Cohen, MD (Cleveland Clinic)	Dr. Cohen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Convelo. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria. Dr. Cohen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Viatris. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PSI. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Cohen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celltrion.
Anand V. Patel, MD (University of Texas Medical Branch)	Dr. Patel has nothing to disclose.
	No disclosure on file
Archana Hinduja, MD	Dr. Hinduja has nothing to disclose.

��ɫ��

��ɫ��